Alto Neuroscience (NYSE:ANRO) Trading Up 8.1% – Should You Buy?

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price traded up 8.1% during trading on Friday . The company traded as high as $16.99 and last traded at $17.1750. 57,117 shares were traded during mid-day trading, a decline of 74% from the average session volume of 223,309 shares. The stock had previously closed at $15.89.

Wall Street Analysts Forecast Growth

ANRO has been the subject of a number of recent research reports. Chardan Capital raised their target price on Alto Neuroscience from $15.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Robert W. Baird lifted their price objective on Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. BTIG Research started coverage on shares of Alto Neuroscience in a research report on Monday, November 17th. They set a “buy” rating and a $27.00 target price for the company. Finally, Jefferies Financial Group boosted their price target on shares of Alto Neuroscience from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Alto Neuroscience has a consensus rating of “Moderate Buy” and a consensus price target of $26.33.

Alto Neuroscience Trading Up 3.2%

The firm’s 50 day moving average is $15.11 and its 200 day moving average is $8.27. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The company has a market cap of $509.55 million, a PE ratio of -7.16 and a beta of 2.78.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.14. On average, equities analysts anticipate that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can bought a new position in shares of Alto Neuroscience in the second quarter worth approximately $25,000. Ground Swell Capital LLC purchased a new position in Alto Neuroscience in the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Alto Neuroscience during the second quarter valued at about $33,000. AlphaCore Capital LLC raised its position in Alto Neuroscience by 100.0% during the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $44,000 after purchasing an additional 10,000 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Alto Neuroscience in the 1st quarter worth approximately $52,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.